Glucagon-like peptide-1 (GLP-1) agonists have become a cornerstone in the management of type 2 diabetes mellitus (T2DM), encompassing agents such as exenatide, liraglutide, and dulaglutide. This evidence concerns the gene GCG and type 2 diabetes mellitus.